Biofrontera
BFRI
14 hedge funds and large institutions have $729K invested in Biofrontera in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
0.65% less ownership
Funds ownership: 3.63% → 2.98% (-0.65%)
13% less funds holding
Funds holding: 16 → 14 (-2)
19% less capital invested
Capital invested by funds: $900K → $729K (-$171K)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.27K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.6K |
| 3 |
Renaissance Technologies
New York
|
+$6.13K |
| 4 |
QC
Quent Capital
New York
|
+$1.82K |
| 5 |
BlackRock
New York
|
+$1.43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
Bard Associates
Chicago,
Illinois
|
-$56.2K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$19K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$5K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.51K |
| 5 |
Jane Street
New York
|
-$4.11K |
BFRI Hedge Fund Activity: Q4 2022 in Review
14 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Biofrontera (BFRI) for Q4 2022, worth a combined $729K — down 19% from $900K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BFRI and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 6 added.
The largest buyer was Geode Capital Management, adding an estimated $9.27K. The largest seller was Bard Associates, cutting an estimated $56.2K.
- 14 institutional investors held Biofrontera (BFRI) as of Q4 2022, down from 16 in Q3 2022.
- Funds reported $729K of Biofrontera stock for Q4 2022, down 19% quarter-over-quarter.
- 2 funds opened new Biofrontera positions in Q4 2022 and 4 closed out, a net change of -2 holders.
- The largest Biofrontera buyer in Q4 2022 was Geode Capital Management, an estimated $9.27K added.
- The largest Biofrontera seller in Q4 2022 was Bard Associates, an estimated $56.2K sold.
Based on aggregated 13F filings for Q4 2022.